NFKB1 and inflammatory response: However, 12 weeks of RESV-treatment contributed to the moderation of cardiac inflammation by decreasing MPO activity, the expression of TNF-α and NFκB. Confirming our results, both in vivo and in vitro studies substantiated the anti-inflammatory properties of RESV trough the inhibition of inflammatory factors and pathways [34].